Frontlight ResearchEarly access
Active, not recruitingPhase 3
Neostigmine and Glycopyrrolate by Iontophoresis
Key facts
- Who runs it
- James J. Peters Veterans Affairs Medical Center
- Where
- The Bronx, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 6 people enrolled
- Started
- 6 Nov 2020
- Ended
- 1 Jan 2025
- Type of study
- Interventional
- Treatments tested
- Combination of Neostigmine and Glycopyrrolate
- I-Box by Dynatronics
- Record updated
- 8 April 2024
Who can take part
- Age
- 18 years to 89 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (25)Hide the full registry criteria
Who can take part
- Male or female
- Age 18 to 89
- Chronic SCI (>1 year post injury)
- You have documented constipation/difficulty with bowel evacuation and/or experience pain, straining, or fecal incontinence
Who cannot take part
- Previous adverse reaction or hypersensitivity to electrical stimulation
- Known sensitivity (prior reaction or allergy) to neostigmine or glycopyrrolate
- Concurrent illness (with or without fever), such as lower respiratory illnesses, increased mucous/secretin production, congestive heart failure (CHF), or pneumonia
- Currently taking cholinesterase inhibitors, such as those for Parkinson's Disease (PD) or dementia (rivastigmine, donepezil etc.), or medication with anticholinergic activity, such as anti-depressants
- Concurrent participation in a research study
- History of mechanical obstruction (physical blockage) of the GI or urinary tract (e.g., due to scar tissues forming after surgery, gallstones)
- Myocardial infarction (heart attack) within 6 months of trial
- Malignant and/or uncontrollable hypertension (high blood pressure), defined as a blood pressure reading of 160/100 mmHg or higher with or without taking 3 or more different classes of anti-hypertensive medications (drugs used to treat high blood pressure)
- Organ damage (heart \& kidney) and/or transient ischemic attack/cerebrovascular accident (TIA-CVA, or stroke) as a result of hypertension
- Known past history of coronary artery disease or bradyarrhythmia (slow heart rate)
- Inability to provide informed consent determined by Montreal Cognitive Assessment Test (MoCA) score of 20 or less. This test is used to detect mild cognitive impairment
- History of ingrown hair folliculitis (inflammation of hair follicles)
- Chronic gastrointestinal (GI) disease such as inflammatory bowel disease (IBD), irritable bowel syndrome with constipation (IBS-C), or other causes of difficulty with stool evacuation such as hypothyroidism (underactive thyroid)
- Fever (as an isolated symptom without "illness"), or who may be exposed to high environmental temperatures
- Currently taking the following medications: Bethanechol, Chloroquine, Colistin, Penicillamine, Lithium, Methylcellulose, Trimeprazine, Verapamil, Phenothiazines, Sparfloxacin, Amitriptyline, Doxepin, Imipramine, Potassium chloride, Saquinavir, Dronedarone, Cisapride, Bepridil, Terfenadine, Amiodarone, Ziprasidone, or any medication(s) that could result in adverse reactions with neostigmine and/or glycopyrrolate, as determined by a study physician
- EKG abnormalities such as bradycardia, prolonged QTc interval, axis shift, bundle branch block, Wolff-Parkinson-White Syndrome (WPW syndrome), 2nd and 3rd degree heart blocks etc. (determined at screening 12-lead EKG)
- Symptomatic orthostatic hypotension (low blood pressure with possible dizziness/fainting)
- Deep brain stimulation
- Pregnancy (women who are sexually active and of childbearing potential must utilize a method of contraception and agree to maintain a contraceptive method until completion of the study)
- Lactating, nursing females
- Myasthenia gravis
Where in United States
- James J. Peters Veterans Affairs Medical CenterThe Bronx, United States
About the trial
What the trial wants to find out
To determine a lower effective dose of neostigmine to induce bowel evacuation by transcutaneous administration by iontophoresis.
The group in the trial
- PrimaryTreatment being tested
Subjects will receive medication administration intravenously, then through a wired ION system of NEO + GEO.
Treatment: Combination of Neostigmine and Glycopyrrolate and I-Box by Dynatronics
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neostigmine and Glycopyrrolate by Iontophoresis to Induce Bowel Evacuation
- Record updated
- 8 April 2024